US · NNNN
Anbio Biotechnology Class A Ordinary Shares
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Frankfurt am Main 60437
- Website
- anbio.com
Price · as of 2024-12-31
$28.90
Market cap 1.13B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $27.94 | -3.32% |
| Intrinsic Value(DCF) | $3.10 | -89.27% |
| Graham-Dodd Method(GD) | $0.69 | -97.62% |
| Graham Formula(GF) | $1.64 | -94.34% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $0.43 | $29.29 | |||
| 2023 | $0.18 | $0.00 | |||
| 2024 | $6.93 | $27.94 | $6.88 | $0.69 | $1.64 |
AI valuation
Our deep-learning model estimates Anbio Biotechnology Class A Ordinary Shares's (NNNN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $27.94
- Current price
- $28.90
- AI upside
- -3.32%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.10
-89.27% upside
Graham-Dodd
$0.69
-97.62% upside
Graham Formula
$1.64
-94.34% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NNNN | Anbio Biotechnology Class… | $28.90 | 1.13B | -3% | -89% | -98% | -94% | 123.51 | 17.05 | 35.81 | 109.60 | 33.69 | 17.05 | 71.90% | 24.38% | 28.99% | 14.83% | 37.79% | 13.66% | 0.00 | — | 10.71 | 7.41 | -4.58 | 36667.00% | 2195.00% | 13157.00% | 0.71% | 1.20 | 39.40% | 0.00% | 0.00% | 0.71% | 140.99 | 135.22 | 34.37 | 104.75 |
| ANGO | AngioDynamics, Inc. | $11.44 | 471.53M | +233% | -70% | -97% | — | -10.26 | 1.91 | 1.19 | 168.52 | — | 3.06 | 53.92% | -13.66% | -11.62% | -17.50% | -30.54% | -11.37% | 0.00 | — | 2.21 | 1.30 | -32.16 | -8192.00% | -376.00% | -5699.00% | -4.18% | -0.13 | -11.17% | 0.00% | 0.00% | 0.48% | -7.33 | -20.07 | 1.00 | 0.98 |
| AVNS | Avanos Medical, Inc. | $14.10 | 654.51M | +97% | -60% | -93% | — | -8.90 | 0.83 | 0.93 | -20.72 | — | 2.44 | 49.77% | -8.78% | -9.68% | -9.07% | -7.21% | -6.54% | 0.17 | -15.40 | 2.15 | 1.17 | -1.18 | -8288.00% | 195.00% | -4801.00% | 6.64% | 0.45 | 5.05% | 0.00% | 0.00% | 3.58% | -11.17 | 15.96 | 0.98 | 0.98 |
| CLPT | ClearPoint Neuro, Inc. | $12.57 | 373.94M | +192% | -56% | — | — | -18.68 | 13.91 | 11.25 | -18.87 | — | 14.18 | 60.92% | -62.91% | -60.25% | -81.24% | -189.62% | -46.22% | 0.14 | — | 3.22 | 2.40 | 0.93 | -2222.00% | 3104.00% | -3610.00% | -2.61% | -0.86 | -88.59% | 0.00% | 0.00% | 2.08% | -17.05 | -36.50 | 10.73 | 8.37 |
| CMPS | COMPASS Pathways plc | $6.90 | 662.41M | — | — | — | — | -1.63 | 1.63 | — | -0.80 | — | 1.63 | 0.00% | — | — | -81.55% | -590.05% | -63.36% | 0.21 | -39.79 | 5.92 | 5.49 | 0.89 | -86.00% | — | 2231.00% | -47.22% | -3.50 | -394.64% | 0.00% | 0.00% | 0.00% | -0.67 | -1.00 | — | -2.75 |
| CYH | Community Health Systems,… | $3.46 | 479.28M | +184% | -61% | — | +667% | 0.67 | -0.33 | 0.04 | 5.83 | — | -0.09 | 8.67% | -79.42% | 4.08% | -40.87% | -92.22% | 4.96% | -8.31 | -11.40 | 1.46 | 1.06 | 5.60 | -19667.00% | -118.00% | 7333.00% | 45.79% | 0.25 | 2.07% | 0.00% | 0.00% | 164.44% | -1.19 | 56.61 | 0.94 | -1.80 |
| GOSS | Gossamer Bio, Inc. | $0.42 | 98.35M | — | +201% | — | — | -4.84 | 9.28 | 2.39 | -4.56 | — | 9.28 | 100.00% | -52.24% | -49.28% | -122.54% | 143.80% | -18.03% | 6.88 | -5.20 | 6.88 | 6.66 | -3.92 | -7881.00% | — | -9782.00% | -1.27% | -0.08 | 8.32% | 0.00% | 0.00% | 8.83% | -3.04 | -52.51 | 1.59 | -4.31 |
| KALV | KalVista Pharmaceuticals,… | $16.28 | 822.89M | — | — | — | — | -3.93 | 7.56 | — | -3.11 | -54.08 | 7.56 | 0.00% | — | — | -121.50% | 456.02% | -75.46% | 0.07 | -32.50 | 5.35 | 4.49 | 0.53 | 727.00% | — | 7100.00% | -21.27% | -3.39 | 371.96% | 0.00% | 0.00% | 9.41% | -2.87 | -3.52 | — | -2.40 |
| RIGL | Rigel Pharmaceuticals, In… | $34.74 | 630.58M | +1,555% | +15% | -85% | +70% | 20.63 | 109.71 | 2.01 | 12.04 | — | -15.15 | 89.60% | 13.49% | 9.75% | -137.92% | -117.91% | 12.44% | 18.24 | 3.06 | 2.13 | 1.88 | 0.11 | -16875.00% | 5338.00% | -24981.00% | 8.61% | 0.50 | -159.09% | 0.00% | 0.00% | 9.58% | 14.19 | 11.05 | 1.92 | -8.42 |
| SNDL | SNDL Inc. | $1.54 | 396.55M | +1,401% | +62% | -9% | — | -5.99 | 0.51 | 0.63 | -11.63 | — | 0.61 | 26.11% | -11.28% | -10.30% | -8.20% | -8.54% | -6.82% | 0.13 | -13.49 | 5.10 | 3.06 | 1.60 | -4162.00% | 126.00% | -27858.00% | 7.62% | 0.61 | 3.96% | 0.00% | 0.00% | 8.92% | -4.62 | 10.92 | 0.52 | 0.99 |
| TALK | Talkspace, Inc. | $4.82 | 807.19M | +644% | +552% | -81% | -72% | -159.22 | 7.10 | 3.63 | 65.62 | -30.89 | 7.30 | 42.97% | 1.38% | 3.40% | -4.45% | 24.45% | -3.81% | 0.00 | — | 6.38 | 6.25 | -3.32 | 51538.00% | 2200.00% | -13365.00% | -0.25% | 0.49 | -17.55% | 0.00% | 0.00% | 2.07% | 234.06 | -350.15 | 3.22 | 27.81 |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
- CEO
- Michael Lau
- Employees
- 27
- Beta
- 9.83
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.10 ÷ $28.90) − 1 = -89.27% (DCF, example).